
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67 million. Xenon Pharmaceuticals collected $3.74 million in revenue during Q4, but reported earnings showed a $25.56 million loss.